Clinical implications of tumor necrosis factor receptor 2 in breast cancer

Yang,Fuqian; Zhao,Zhonghua; Zhao,Nana

doi:10.3892/ol.2017.6410

Clinical implications of tumor necrosis factor receptor 2 in breast cancer

Authors:
- Fuqian Yang
- Zhonghua Zhao
- Nana Zhao
View Affiliations

Affiliations: Department of Breast Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Oncology, The Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong 256600, P.R. China, Department of Medical Examination, Fangzi People's Hospital, Weifang, Shandong 261000, P.R. China
Published online on: June 19, 2017 https://doi.org/10.3892/ol.2017.6410
Pages: 2393-2398

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor receptor 2 (TNFR2) is a member of the tumor necrosis factor receptor family. Its high expression and oncogenic roles have been reported in several types of tumors in previous years. However, the clinical implication of TNFR2 in breast cancer (BC) tissue (i.e., not soluble TNFR2 in blood or genetic variation of TNFR2) has not been reported. In the present study, TNFR2 expression was detected in BC tissue using immunohistochemistry and, to the best of our knowledge, it was confirmed for the first time that TNFR2 was positively associated with increased tumor size, advanced clinical stage and higher pathological grade. Survival analysis revealed that TNFR2 was positively associated with shorter overall survival (OS) time and disease‑free survival (DFS) time. In addition, univariate regression analysis demonstrated that TNFR2 expression (P=0.045), tumor size (P<0.0001), clinical stage (P<0.0001), pathological grade (P=0.002), estrogen and progesterone receptor and human epidermal growth factor receptor 2 (HER2) triple‑status (P=0.001) all had a significant impact on the OS rate of patients with BC. TNFR2 expression (P=0.017), age (P=0.011), menopausal status (P<0.0001), tumor size (P=0.016), clinical stage (P=0.005), pathological grade (P=0.002) and estrogen/progesterone receptor and HER2 triple‑status (P=0.008) were all shown to significantly impact the DFS rate of patients with BC. Multivariate regression analysis showed that only clinical stage (P=0.024), estrogen and progesterone receptor status and HER2 status (P=0.009) had a significant impact on the OS rate of patients with BC, while TNFR2 expression (P=0.043) and menopausal status (P=0.033) were shown to significantly impact the DFS rate of patients with BC. These data indicated that TNFR2 may perform important roles in the progression and prognosis of BC. This enriches previous understanding about TNFR2 in BC.

View Figures

View References

1	Riaz SK, Saeed M and Malik MF: Clinical and therapeutic implications of histone acetylation in breast cancer. West Indian Med J. May 6–2015.(Epub ahead of print). View Article : Google Scholar
2	Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, et al: Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 56:85–92. 2016. View Article : Google Scholar : PubMed/NCBI
3	Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, Combs SE and Multhoff G: Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. Radiother Oncol. 118:176–180. 2016. View Article : Google Scholar : PubMed/NCBI
4	Smoot B, Paul SM, Aouizerat BE, Dunn L, Elboim C, Schmidt B, Hamolsky D, Levine JD, Abrams G, Mastick J, et al: Predictors of altered upper extremity function during the first year after breast cancer treatment. Am J Phys Med Rehabil. 95:639–655. 2016. View Article : Google Scholar : PubMed/NCBI
5	Partridge AH: Chemotherapy in premenopausal breast cancer patients. Breast Care (Basel). 10:307–310. 2015. View Article : Google Scholar : PubMed/NCBI
6	Zhu YY, Si W, Ji TF, Guo XQ, Hu Y and Yang JL: The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. Tumour Biol. 37:7675–7684. 2016. View Article : Google Scholar : PubMed/NCBI
7	Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE and Wu EQ: Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: A physician survey. Cancer Med. 5:209–220. 2016. View Article : Google Scholar : PubMed/NCBI
8	Rossi L and Pagani O: The modern landscape of endocrine therapy for premenopausal women with breast cancer. Breast Care (Basel). 10:312–315. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hosono K, Yamada E, Endo H, Takahashi H, Inamori M, Hippo Y, Nakagama H and Nakajima A: Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas. World J Gastroenterol. 18:5360–5368. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, et al: The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 332:478–484. 2011. View Article : Google Scholar : PubMed/NCBI
11	Guo Z, Li Q, Han Y, Liang Y, Xu Z and Ren T: Prevention of LPS-induced acute lung injury in mice by progranulin. Mediators Inflamm. 2012:5407942012. View Article : Google Scholar : PubMed/NCBI
12	Zhao YP, Tian Q, Frenkel S and Liu CJ: The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling. Biomaterials. 34:6412–6421. 2013. View Article : Google Scholar : PubMed/NCBI
13	Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG and Balkwill FR: Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene. 23:1902–1910. 2004. View Article : Google Scholar : PubMed/NCBI
14	Tanimura Y, Kokuryo T, Tsunoda N, Yamazaki Y, Oda K, Nimura Y, Mon N Naing, Huang P, Nakanuma Y, Chen MF, et al: Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Lett. 219:205–213. 2005. View Article : Google Scholar : PubMed/NCBI
15	Jöhrer K, Janke K, Krugmann J, Fiegl M and Greil R: Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res. 10:1901–1910. 2004. View Article : Google Scholar : PubMed/NCBI
16	Grotowski M and Wojtuń S: CEA, CA-19-9 and il-8, sTNFRII and sil-2R in persons at high risk of colorectal cancer. Pol Merkur Lekarski. 14:327–330. 2003.(In Polish). PubMed/NCBI
17	Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, Löffler M, Jung W, Pfreundschuh M, Trümper L and Kube D: Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res. 18:3637–3647. 2012. View Article : Google Scholar : PubMed/NCBI
18	Jablonska E: Release of soluble IL-6 receptor (IL-6sR) in comparison with release of soluble TNF receptors (sTNF-Rs) by PMNs and WBC derived from breast cancer patients. Cancer Lett. 119:79–85. 1997. View Article : Google Scholar : PubMed/NCBI
19	Tesarová P, Kvasnicka J, Umlaufová A, Homolková H, Jirsa M and Tesar V: Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit. 6:661–667. 2000.PubMed/NCBI
20	Xu F, Zhou G, Han S, Yuan W, Chen S, Fu Z, Li D, Zhang H, Li D and Pang D: Association of TNF-α, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women. PLoS One. 9:e1011382014. View Article : Google Scholar : PubMed/NCBI
21	Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, Ooi CJ, Xavier RJ, Terhorst C, Podolsky DK and Bhan AK: Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology. 122:134–144. 2002. View Article : Google Scholar : PubMed/NCBI
22	Mestiri S, Bouaouina N, Ben Ahmed S and Chouchane L: A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine. 30:182–187. 2005. View Article : Google Scholar : PubMed/NCBI
23	García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R and Royuela M: Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci. 97:1044–1049. 2006. View Article : Google Scholar : PubMed/NCBI
24	Yang D, Wang LL, Dong TT, Shen YH, Guo XS, Liu CY, Liu J, Zhang P, Li J and Sun YP: Progranulin promotes colorectal cancer proliferation and angiogenesis through TNFR2/Akt and ERK signaling pathways. Am J Cancer Res. 5:3085–3097. 2015.PubMed/NCBI
25	Mouttet D, Laé M, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Vincent-Salomon A, Rouzier R, Sigal-Zafrani B, Sastre-Garau X and Reyal F: Estrogen-receptor, progesterone-receptor and HER2 status determination in invasive breast cancer. Concordance between immuno-histochemistry and MapQuant microarray based assay. PLoS One. 11:e01464742016. View Article : Google Scholar : PubMed/NCBI
26	Pizot C, Boniol M, Mullie P, Koechlin A, Boniol M, Boyle P and Autier P: Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. Eur J Cancer. 52:138–154. 2016. View Article : Google Scholar : PubMed/NCBI
27	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
28	Chai P, Tian J, Zhao D, Zhang H, Cui J, Ding K and Liu B: GSE1 negative regulation by miR-489-5p promotes breast cancer cell proliferation and invasion. Biochem Biophys Res Commun. 471:123–128. 2016. View Article : Google Scholar : PubMed/NCBI
29	Richards P, Ward S, Morgan J, Lagord C, Reed M, Collins K and Wyld L: The use of surgery in the treatment of ER+ early stage breast cancer in England: Variation by time, age and patient characteristics. Eur J Surg Oncol. 42:489–496. 2016. View Article : Google Scholar : PubMed/NCBI
30	Qiu J, Xue X, Hu C, Xu H, Kou D, Li R and Li M: Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer. 7:167–173. 2016. View Article : Google Scholar : PubMed/NCBI
31	Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK and Gudjonsson T: HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR. Oncogene. 35:4244–4255. 2016. View Article : Google Scholar : PubMed/NCBI